Publication details

Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib

Authors

SMETANA Jan BERÁNKOVÁ Kristina ZAORALOVÁ Romana NĚMEC Pavel GREŠLIKOVÁ Henrieta KUPSKÁ Renata MIKULÁŠOVÁ Aneta FRÖHLICH Jan ŠEVČÍKOVÁ Sabina ZAHRADOVÁ Lenka KREJČÍ Marta SANDECKÁ Viera ALMAŠI Martina KAISAROVÁ Petra MELICHAROVÁ Hana ADAM Zdeněk PENKA Miroslav JARKOVSKÝ Jiří JURCZYSZYN Arthur HÁJEK Roman KUGLÍK Petr

Year of publication 2013
Type Article in Periodical
Magazine / Source Clinical lymphoma, myeloma & leukemia
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1016/j.clml.2012.11.012
Field Oncology and hematology
Keywords Multiple myeloma; Thalidomide; Bortezomib; Chromosomal aberrations; FISH; Survival
Attached files
Description Prognostic impact of specific chromosomal aberrations in patients with relapsed multiple myeloma (MM) treated with the novel agents is briefly described. We analyzed the prognostic value of an extended panel of chromosomal aberrations [del(13)(q14), del(17)(p13), t(4;14)(p16;q32), gain(1)(q21), and hyperdiploidy] by using the technique of interphase fluorescence in situ hybridization in a cohort of 102 patients with relapsed MM treated with thalidomide- or bortezomib-based protocols. We conclude that bortezomib-based protocols are able to partially overcome the negative prognostic impact of the tested chromosomal abnormalities in patients with relapsed MM.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info